Placebo-controlled biofeedback blood pressure effect in hypertensive humans.

The role of biofeedback in blood pressure control remains ill-defined because of nonspecific (placebo) effects, small study numbers, and the technical limitations of continuous pressure feedback. Clarification of its potential is awaited by those seeking a nonpharmacological approach to blood pressure control. This study examines the capability for systolic pressure lowering of 5 mm Hg or more using continuous pressure feedback in a statistical sample of untreated, well-characterized, mildly hypertensive individuals. Subjects were randomized in a double-blind study to active or placebo biofeedback. Placebo consisted of a modified contingency approach, using a partial disguise based on a digital high pass filter with 15 elements. Blood pressure-lowering capability was assessed during two laboratory sessions. Continuous visual feedback resulted in 11 of 28 subjects on active treatment and 12 of 28 on placebo treatment lowering their systolic pressure by 5 mm Hg or more (11 +/- 5.6 and 12 +/- 8.4 mm Hg, respectively; P = NS). Prestudy pressure was well-matched (153 +/- 9/97 +/- 4 and 154 +/- 8/98 +/- 4 mm Hg, respectively). An initial small difference in diurnal profile did not change. These findings indicate that among mildly hypertensive individuals, almost half can lower systolic pressure at will for short periods. This capability is independent of the real or placebo nature of the feedback signal. We conclude that there is no specific short-term biofeedback pressure-lowering capability in hypertensive individuals. Further exploration is needed to determine whether specific components of the placebo effect can be delineated, whether personality characteristics influence the response, and whether further biofeedback training can alter the outcome.

[1]  C. Berkey,et al.  Cognitive Behavioral Techniques for Hypertension: Are They Effective? , 1993, Annals of Internal Medicine.

[2]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[3]  L. DiCara.  Instrumental learning of urine formation by rats; changes in renal blood flow. , 1968 .

[4]  D. Sackett,et al.  The Ends of Human Life: Medical Ethics in a Liberal Polity , 1992, Annals of Internal Medicine.

[5]  H. Kotses,et al.  Operant reduction of frontalis EMB activity in the treatment of asthma in children. , 1976, Journal of psychosomatic research.

[6]  M. Prins,et al.  Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. , 1991, The American journal of cardiology.

[7]  M. Marmot,et al.  Controlled trial of biofeedback-aided behavioural methods in reducing mild hypertension. , 1981, British medical journal.

[8]  B. Wallin,et al.  Sympathetic outflow to muscles during treatment of hypertension with metoprolol. , 1984, Hypertension.

[9]  S. Hunyor,et al.  The role of stress management in blood pressure control: why the promissory note has failed to deliver. , 1996, Journal of hypertension.

[10]  G. Viol,et al.  An incremental model to isolate specific effects of behavioral treatments in essential hypertension , 1993, Biofeedback and self-regulation.

[11]  J. Chalmers,et al.  Brainstem and bulbospinal neurotransmitter systems in the control of blood pressure. , 1991, Journal of hypertension.

[12]  J. Cassel,et al.  Psychosocial factors in essential hypertension. Recent epidemiologic and animal experimental evidence. , 1969, American journal of epidemiology.

[13]  J. Kelly,et al.  Evaluation of the reproducibility and accuracy of ambulatory blood pressure monitoring using the Takeda TM-2420 automated blood pressure monitor. , 1993, Clinical and experimental hypertension.

[14]  S N Hunyor,et al.  A continuous non-invasive blood pressure monitor , 1991 .

[15]  M. Hart,et al.  Physiological influences on continuous finger and simultaneous intra-arterial blood pressure. , 1995, Hypertension.

[16]  Cognitive and physiologic responses to EMG biofeedback and three types of pseudofeedback during a muscular relaxation task , 1983, Biofeedback and self-regulation.

[17]  W A Littler,et al.  Sleep and blood pressure. , 1975, British medical journal.

[18]  S. Julius,et al.  Autonomic nervous system dysregulation in human hypertension. , 1991, The American journal of cardiology.

[19]  Schappert Sm.  National Ambulatory Medical Care Survey: 1992 summary. , 1994, Advance data.

[20]  J. Reid,et al.  Brain and autonomic mechanisms in hypertension. , 1994, Journal of hypertension.

[21]  S. Petersen,et al.  The pulvinar and visual salience , 1992, Trends in Neurosciences.

[22]  Walter Dandy,et al.  The Brain , 1966 .

[23]  G. Jennings,et al.  Biochemical evidence of sympathetic hyperactivity in human hypertension. , 1991, Hypertension.

[24]  John J. Furedy,et al.  Specific versus placebo effects in biofeedback: Some brief back-to-basics considerations , 1987, Biofeedback and self-regulation.

[25]  B Julesz,et al.  Early vision is bottom-up, except for focal attention. , 1990, Cold Spring Harbor Symposia on Quantitative Biology.

[26]  Carl E. Sherrick,et al.  Basic and applied research on tactile aids for deaf people: Progress and prospects , 1984 .

[27]  H. Kraemer,et al.  Combining Behavioral Treatments to Reduce Blood Pressure , 1985 .

[28]  H. Spitzer,et al.  Increased attention enhances both behavioral and neuronal performance. , 1988, Science.

[29]  J. G. Carlson,et al.  Expectancies of reinforcement control in biofeedback and cognitive performance , 1981, Biofeedback and self-regulation.

[30]  J. Ockene.  Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. , 1985, The American journal of cardiology.

[31]  R. Bartrop,et al.  VOLUNTARY BLOOD PRESSURE CONTROL USING CONTINUOUS SYSTOLIC BLOOD PRESSURE BIOFEEDBACK , 1988, Clinical and experimental pharmacology & physiology.

[32]  M. Noble,et al.  Operant conditioning of vasoconstriction. , 1968, Journal of experimental psychology.

[33]  P. Ekman,et al.  Handbook of methods in nonverbal behavior research , 1982 .

[34]  Turakhia Dd.  Biofeedback for hypertension. , 1990, The Journal of the Association of Physicians of India.

[35]  L. Klein.  Compliance and Blood Pressure Control , 1988, Hypertension.

[36]  B. Folkow,et al.  The Importance of Adaptive Changes in Vascular Design for the Establishment and Maintenance of Primary Hypertension, as Studied in Man and in Spontaneously Hypertensive Rat , 1973 .

[37]  A Treisman,et al.  Feature analysis in early vision: evidence from search asymmetries. , 1988, Psychological review.

[38]  S. Kaplan.  The Physiology of Thought , 1950 .

[39]  W. Brown.  Placebo as a Treatment for Depression , 1994, Neuropsychopharmacology.

[40]  Ralph B. D'Agostino,et al.  Blood Pressure as a Risk Factor for Cardiovascular Disease The Framingham Study—30 Years of Follow‐up , 1989, Hypertension.

[41]  F. Messerli,et al.  Systemic haemodynamic effects of biofeedback in borderline hypertension. , 1979, Clinical science.